ImmPACT Bio USA Raises $18M In Series A Financing

immpact bio

ImmPACT Bio USA Inc., a Camarillo, Calif.-based company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, closed a US$ 18m Series A equity financing round.

The financing included OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners.

Founded based on the insights of Prof. Gideon Gross (Migal Research Institute), who collaborated with Prof. Zelig Eshhar to design the first Chimeric Antigen Receptor technologies for T-cells (CAR T), and led by Rick Kendall, Ph.D., CEO, ImmPACT Bio USA is developing a novel set of engineered T-cell therapeutics that target loss of genes in solid tumors. 



Join the discussion